Turn Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TTRX Nasdaq 2830 turntherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Turn Therapeutics Inc.

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout - Jul 11th, 2026 11:02 am
Turn Therapeutics’ stock jumps on AD data and trial expansion - Jul 8th, 2026 5:17 am
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis - Jul 7th, 2026 6:56 am
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Jul 7th, 2026 6:05 am
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Jul 6th, 2026 2:01 pm
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Jun 1st, 2026 6:30 am
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - Mar 1st, 2026 11:08 pm
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Feb 4th, 2026 6:17 am
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Jan 8th, 2026 5:13 am
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - Jan 7th, 2026 2:05 pm
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More - Dec 29th, 2025 5:52 am
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Nov 13th, 2025 6:00 am
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. - Nov 11th, 2025 2:05 pm
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - Nov 11th, 2025 6:00 am
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - Nov 4th, 2025 3:07 pm
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline - Oct 30th, 2025 5:30 am
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones - Oct 22nd, 2025 6:00 am
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025 - Oct 20th, 2025 6:22 am
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors - Oct 15th, 2025 6:00 am
Turn Therapeutics Appoints Arthur Golden to Board of Directors - Oct 14th, 2025 10:07 am